Completion of patient screening in phase III trial of roluperidone to treat negative symptoms in schizophrenia.- Minerva Neurosciences
Related news and insights
HLS Therapeutics Inc. announced that Health Canada has approved the use of Perseris (risperidone for extended-release injectable suspension), 90 mg and 120 mg subcutaneous injection, a novel long-acting injectable of risperidone, for the treatment of schizophrenia in adults
The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for PP 6M (paliperidone palmitate 6-month) for the treatment of adults diagnosed with schizophrenia.
Alkermes plc announced that data from its phase IIIb ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness) study were published in the Journal of Clinical Psychiatry.